Normal phagocytes release reactive oxygen compounds in response to infection, but this defense is lacking in phagocytes of people with CGD. In the current issue of the
, Griffin Rodgers and colleagues at the National Institutes of Health identify a neutrophil granule protein, OLFM4 as a potential therapeutic target for CGD patients.
In a mouse model of CGD, deletion of Olfm4
protected the mice from infection with Staphylococcus aureus
. The protective effect of Olmf4
deletion in CGD mice extended to multiple strains of S. aureus, including a community-associated strain of MRSA. This study suggests that targeting OLMF4 in CGD patients may enhance their ability to fight off bacterial infection.